Introduction
============

Neurosteroids are cholesterol-derived compounds categorized in pregnane neurosteroids (e.g., allopregnanolone), androstane neurosteroids (e.g., androstanediol), and sulfated compounds \[PregS and DHEAS\] ([@B75]). They can be synthesized in the central nervous system, or the compounds themselves or precursors can be taken up from the systemic circulation ([@B8]; [@B60]). One of their main functions in the brain is to modulate excitability by interaction with membrane receptors and ion channels ([@B75]). Accordingly, a therapeutic potential of these compounds or synthetic analogs has been discussed for a variety of brain disorders ([@B75]). Local steroid biosynthesis in rodent and human brain has been studied since 1990s ([@B8]). Expression of key enzymes (e.g., P450 side-chain cleavage enzyme, P450c17) has been demonstrated in the principal neurons of several brain areas and in the microglia and astrocytes (reviewed in: [@B60]; [@B35]; [@B72]). However, the relative contributions of the local synthesis and uptake from blood to CNS levels have still to be clarified and may vary between different neurosteroids. In contrast to the lipophilic unconjugated compounds, especially DHEAS and PregS do not diffuse across membranes at a sufficient rate due to their hydrophilic sulfate moiety. Therefore, this review focuses on DHEAS/PregS membrane transporters in the brain. Both compounds play important roles in age-related memory and learning. They can be formed from the non-sulfated precursors by SULTs with SULT2B1b as a major isoform in the human brain ([@B79]). The ratio of sulfated versus non-sulfated neurosteroids in the brain may be decisive, since sulfation can change the direction of the neuromodulating activity. While for example some non-sulfated neurosteroids such as allopregnanolone are potent positive modulators of GABA type A receptors (for review see [@B17]; [@B75]), DHEAS and PregS have been shown to antagonize the GABA effect on the GABA~A~ receptor ([@B81]) and to be potent allosteric agonists at NMDA receptors ([@B94]; [@B64]). Furthermore, PregS has been shown to directly activate certain TRP channels ([@B33]).

Dheas and Pregs Levels in Plasma, Brain, and Cerebrospinal Fluid (CSF) in Humans
================================================================================

While the serum concentrations of the non-sulfated DHEA and pregnenolone are in the low nM range in men and women ([@B53]; [@B44]), levels of DHEAS are much higher with a slight difference between men (2.3--11.5 μM) and women (1.6--6.2 μM). It should be noted that here total steroid concentrations were measured. Due to the high plasma protein binding (95% for DHEAS; [@B89]) the concentration of the unbound steroids is accordingly lower. Generally, hormone levels decrease with age, exhibiting a maximum in young men and women (∼20 years; [@B53]). Total PregS serum levels in adolescence range between 40 and 140 nM, and increase during pregnancy and at birth ([@B23]; [@B44]). In contrast to DHEAS and PregS serum levels, less information is available on their tissue concentrations in the brain and in the CSF. In the human brain, region-dependent PregS concentrations between 5 and 40 nmol/kg have been reported with the highest levels in the striatum and hypothalamus. DHEAS concentrations were detected in a similar range with the highest levels in the striatum and cerebellum ([@B92]). The CSF concentrations of DHEAS and PregS were much lower compared to the respective serum levels \[serum/CSF ratios: 584 (Preg-conjugates), 19849 (DHEA-conjugates); [@B44]\]. These gradients are due to the fact that both compounds cannot cross the respective barriers by passive diffusion, but depend on selective uptake and efflux proteins. ABC- and solute carrier (SLC)-type transporters may not only be relevant for the transport at the BBB and the blood--CSF barrier in the CP, but also for secretion of these compounds from neurons and glial cells (**Figure [1](#F1){ref-type="fig"}**).

![Schematic illustration of ABC and SLC transporters putatively involved in DHEAS and PregS transport and their proposed localization. **(A)** Structures of DHEAS and PregS. **(B,C)** The ABC proteins BCRP (ABCG2), MRP1, MRP4, and MRP8 (ABCC1, ABCC4, and ABCC11), and the solute carriers OAT3 (SLC22A3), OATP1A2 (SLCO1A2), OATP2B1 (SLCO2B1), and OSTα/ß (SLC51A/B) may be involved in secretion of sulfated steroids from neurons and glial cells and/or in the transport across the BBB **(B)** as well as in transport at the blood--CSF barrier in the CP **(C)**. The arrows indicate the directions of substrate transport. Proteins for which there is little or controversial evidence for expression and localization in the basal or apical membrane are indicated in light orange and by a dashed line. Concentration gradients of DHEAS and PregS across the BBB and in the CP are schematically indicated at the right side.](fphar-09-00354-g001){#F1}

Transporters That May Play a Role in the Transport of Neurosteroids: ABC Transporters
=====================================================================================

ATP-binding cassette proteins can mediate a unidirectional primary active transport of a variety of compounds across membranes. Among the ABC transporters especially ABCG2, also known as the BCRP, and several ABCC/MRP subfamily members are known efflux pumps for conjugated steroids ([@B85]; [@B32]).

BCRP/ABCG2
----------

BCRP/ABCG2 was initially identified as a non-P-glycoprotein and non-MRP-type resistance factor from drug-selected cell lines ([@B24]; [@B63]). Besides anti-cancer drugs like mitoxantrone, BCRP actively transports sulfated steroids such as E~1~-3-S and DHEAS, but not unconjugated or glucuronidated steroids ([@B39]; [@B30]). The K~m~ value for E~1~-3-S calculated in isolated membrane vesicles was in the low μM range (**Table [1](#T1){ref-type="table"}**). In addition, androgens such as dihydrotestosterone (DHT) have been identified as BCRP substrates ([@B38]). In human brain microvessels, ABCG2/BCRP transcript ([@B20]; [@B90]) and protein was detected as one of the most abundant ABC transporters ([@B82]). Immunohistochemistry showed it primarily localized at the apical (luminal) side of the endothelial cells ([@B20]; [@B5]; [@B90]). In addition, it was detected in the apical membrane of the CP epithelium ([@B77]). Hence, BCRP could be involved in limiting the penetration of peripheral DHEAS and other steroids into the brain or facilitating the elimination of brain-derived DHEAS into blood. The apical localization in the CP, on the other hand, indicate that here BCRP is able to transport neurosteroids into the CSF.

###### 

ABC and SLC transporters possibly involved in neurosteroid transport in the brain.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Transporter            CNS expression (mRNA and protein analysis)   CNS localization (immunohistochemistry)                 Steroid substrates\
                                                                                                                              (*K*~m~ value)
  ---------------------- -------------------------------------------- ------------------------------------------------------- -----------------------------
  **ABC Transporters**                                                                                                        

  BCRP (ABCG2)           mRNA:\                                       BBB: apical (luminal) (H, R);\                          E~1~-3-S (6.8 μM)^12,13^\
                         - Total brain^1^\                            CP: apical (H, R)^2,10,11^                              DHEAS^12^\
                         - Isolated brain microvessels (BMV)^2,3^\                                                            DHT^14^
                         Protein:\                                                                                            
                         - BMV (H, M, Mo, R, P)^4,5,6,7,8^\                                                                   
                         - Isolated CP^9^                                                                                     

  MRP1 (ABCC1)           mRNA:\                                       BBB: apical (H, B, M),\                                 E~1~-3-S (+GSH)^21^\
                         - Total brain^1^\                            Basal (abluminal) (R, M);\                              DHEAS (+GSH) (5 μM)^22^\
                         - BMV^3^\                                    CP: basal (H, R)^17,18,19,20^                           E~2~-17βG (1.5 μM)^23^
                         - Isolated CP^15^\                                                                                   
                         Protein:\                                                                                            
                         - Isolated CP (H, R)^9,16^                                                                           

  MRP4 (ABCC4)           mRNA:\                                       BBB: apical (H, M, R),\                                 DHEAS (2 μM)^22^\
                         - Total brain^1^\                            Apical + basal (B);\                                    E~2~-17βG (30 μM)^22,25^
                         - BMV^3^\                                    CP: basal (H, R); Astrocytes^3,11,19,20,24^             
                         - Isolated CP^15^\                                                                                   
                         Protein:\                                                                                            
                         - BMV (H, M, Mo, R)^4,5,6,7^\                                                                        
                         - Isolated CP^9^                                                                                     

  MRP8 (ABCC11)          mRNA:\                                       Neurons (axonal;\                                       E~1~-3-S (\>150 μM)^27^\
                         - Total brain^1^                             cerebellum, cortex)^26^                                 DHEAS (13--21 μM)^26,27^\
                                                                                                                              E~2~-17βG (63 μM)^27^

  **SLC Transporters**                                                                                                        

  OATP1A2 (SLCO1A2)      mRNA:\                                       BBB: luminal; amacrine neurons^28,29,30,31^             DHEAS (7 μM)^32^\
                         - Total brain^1^\                                                                                    E~1~-3-S (16 μM)^31^
                         Protein:\                                                                                            
                         - BMV (M, Mo)^5,6^                                                                                   

  OATP2B1 (SLCO2B1)      mRNA:\                                       BBB: luminal; CP\                                       E~1~-3-S (5--21 μM)^34,35^\
                         - Total brain^1^\                            (ependymal cells) (R);\                                 DHEAS (9 μM)^35^ PregS^36^
                         Protein:\                                    amacrine neurons^11,29,30,33^                           
                         - Brain capillary cells^31^ - BMV (M)^6^                                                             

  OATP3A1 (SLCO3A1)      mRNA:\                                       CP; neurons^37^                                         E~1~-3-S^38^
                         - Total brain^1^\                                                                                    
                         Protein:\                                                                                            
                         - Isolated CP^9^\                                                                                    
                         - BMV (P)^8^                                                                                         

  OAT3 (SLC22A3)         mRNA:\                                       BBB: basal (R);\                                        E~1~-3-S (8.8 μM)^42^\
                         - Total brain^1^\                            CP: basal (H, R)^39,40,11,41^                           DHEAS^42^
                         Protein:\                                                                                            
                         - Isolated CP^9^\                                                                                    
                         - BMV (R)^7^                                                                                         

  OSTα-OSTβ (SLC51A/B)                                                Neurons (cerebellum, Hippocampus; Purkinje cells)^43^   DHEAS (1.5 μM)^43^\
                                                                                                                              PregS (6.9 μM)^43^
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

Unless otherwise specified, the data refer to human tissue and transporter protein. B, bovine; BBB, blood--brain barrier (capillary endothelial cells); BMV, isolated brain microvessels; CP, choroid plexus; DHEAS, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; E

1

-3-S, estrone-3-sulfate; E

2

-17βG, estradiol-17 β-glucuronide; H, human; M, mouse; Mo, monkey; P, pig; R, rat; PregS, pregnenolone sulfate.
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Members of the MRP/ABCC Family
------------------------------

Anionic conjugates of lipophilic compounds are typical substrates for several members of the MRP family. As the founding member, MRP1 (ABCC1) was identified as second export pump conferring a multidrug resistance phenotype besides the MDR1/P-glycoprotein (ABCB1) ([@B19]). MRP1 was subsequently shown to preferentially transport amphiphilic anions, especially conjugates of lipophilic compounds with glutathione, glucuronate, or sulfate ([@B42]; [@B58]). MRP1 transports in addition certain cationic or uncharged compounds, but only in co-transport with reduced glutathione (GSH; [@B58]). It also mediates the transport of E~1~-3-S and of DHEAS in a glutathione-dependent manner ([@B73]; [@B95]) and is expressed in several tissues ([@B32]). It is also expressed in brain microvessels ([@B90]); however, the exact localization and function has not been finally clarified. It was detected to be luminal in humans, bovine, and murine brain ([@B67]; [@B96]), but also localization at the basolateral (abluminal) membrane was described in mice and rats ([@B48]; [@B77]). Some groups did not detect MRP1 protein in human brain capillaries at all ([@B74]; [@B5]). Because of the inconsistent and low-level expression, the relevance of this transporter at the BBB is so far unclear. It may play a more important role in the CP. Here, MRP1 mRNA was detected in rat and human tissue ([@B28]; [@B66]) and the protein was localized at the basolateral membrane ([@B74]; [@B93]; [@B28]). Thus, it may be involved in the efflux of conjugated steroids from the CSF into blood. In addition, MRP1 mRNA was detected in cultured rat and human astrocytes ([@B34]; [@B83]). However, the protein could not been detected in human glial cells or neurons in immunohistochemical studies ([@B67]; [@B5]). MRP1 and MRP2 (ABCC2) share a similar substrate spectrum, but MRP2 is mainly expressed in polarized epithelial cells ([@B46]). Immunostaining at the apical membrane in brain capillaries was described in rats ([@B61]), but was not observed in human and bovine brain ([@B67]; [@B96]). Similarly, MRP3 (ABCC3) protein was not detected in human brain ([@B67]).

A more relevant efflux transporter for conjugated steroids in the brain may be MRP4/ABCC4, which exhibits a unique broad substrate specificity. MRP4 shows the remarkable capacity to transport cyclic nucleotides and MRP4 has been established as an independent regulator of intracellular cAMP levels in several cell types ([@B76]; [@B41]; [@B9]). Furthermore, MRP4 transports lipid mediators such as prostanoids and conjugated steroids. DHEAS is transported by MRP4 in a glutathione-independent manner and with high affinity (K~m~ of 2 μM; [@B95]). It is expressed in several tissues especially in the prostate, kidney, blood cells, and brain ([@B50]; [@B32]; [@B68]; [@B66]; [@B90]; [@B82]). Here, it was localized apically in human, rodent and bovine capillaries ([@B67]; [@B55]; [@B96]; [@B77]). An additional detection at the basolateral membrane was only described in bovine brain ([@B96]). MRP4 expression was also detected in human CP ([@B66]; [@B88]) and it was localized to the basolateral membrane in human and murine tissue ([@B55]). Moreover, it is expressed in glial cells. Immunofluorescence studies in the human brain revealed staining mainly in astrocytes of the subcortical white matter ([@B67]). Since glial cells are able to synthesize neurosteroids, MRP4 may account for the efflux of DHEAS and other neurosteroids from these cells for a paracrine action. Astrocytes play a critical role for the development and function of neurons and these cells in turn are regulated by steroid hormones as progesterone and DHEA ([@B1]; [@B4]). At the BBB and the CP, MRP4 may contribute to the transport of sulfated steroids from brain and CSF into blood.

A further member of the MRP family, the MRP8 (ABCC11) may be relevant with respect to neurosteroid transport. MRP8 was shown to transport DHEAS in isolated membrane vesicles with a K~m~ value of 13--21 μM, whereas the K~m~ was above 150 μM for MRP8-mediated transport of E~1~-3-S ([@B15]; [@B10]). In immunofluorescence studies, it was detected preferentially in the white matter of the cortex and cerebellum and co-localized with neurofilaments indicating localization in neuronal axons ([@B10]). In addition, weak immunostaining was detected in the gray matter and also in the axons of peripheral neurons. The axonal localization implies that MRP8 can mediate presynaptic efflux of neurosteroids from neurons and thus could directly participate in modulating postsynaptic neurotransmitter receptors ([@B10]).

Uptake (SLC) Transporters
-------------------------

Besides ABC-type efflux transporters, neurosteroid concentrations in the brain may also be modulated by uptake transporters. Since several members of the SLC superfamily have been identified as uptake transporters for steroid conjugates in general, these transporters are interesting candidates for the transport of neurosteroids. In fact, several SLCs have been shown to mediate cellular uptake of DHEAS and PregS.

Members of the OATP/SLCO Family
-------------------------------

Among the SLC transporters, the OATP (SLCO) family is probably the most interesting one in this context. In humans, 11 SLCO transporters exist, organized in six families ([@B31]). The physiological substrate profile of the OATP transporters comprises a wide variety of endogenous organic anions including bile acids, bilirubin, thyroid hormones, and prostaglandins ([@B31]). In addition, OATPs transport steroid hormone conjugates like E~1~-3-S (nearly all OATPs) or estradiol-17β-glucuronide (OATP1A2, OATP1B1, OATP1B3, OATP1C1, and OATP4A1) and the neurosteroid DHEAS (OATP1A2, OATP1B1, OATP1B3, and OATP2B1) ([@B31]). The affinity of these transporters toward DHEAS was slightly above (OATP1B1 and OATP1B3) or in the range (OATP2B1 and OATP1A2) (**Table [1](#T1){ref-type="table"}**) of the physiological plasma concentration (1.6--11.5 μM; [@B53]) indicating an *in vivo* relevance of these findings. OATP1B1 and OATP1B3 are almost exclusively expressed in the human liver. Here, they are responsible for cellular uptake as a prerequisite for hepatic metabolism and elimination. In turn, the expression and function of these transporters affect systemic DHEAS levels as shown by enhanced DHEAS levels in monkeys and rats after treatment with the unspecific OATP inhibitor rifampicin ([@B91]; [@B69]). Assuming a DHEAS transport/uptake from the blood into the brain/CSF ([@B45]), changes in DHEAS plasma concentration might indirectly influence the concentration in these compartments. Therefore, OATPs localized in the BBB and/ or the CP are of special interest. Indeed, OATP1A2, OATP1C1, OATP2B1, and OATP3A1 have been detected in these structures in humans ([@B52]; [@B70]; [@B37]; [@B78]; [@B43]). Since OATP1C1 is a thyroid hormone transporter and the function of OATP3A4 is only poorly understood, at present OATP1A2 and OATP2B1 are probably the most interesting members concerning neurosteroid transport in the brain. Both proteins are expressed in the endothelial cells of the BBB presumably in the luminal membrane predisposing them as transporters for uptake into the brain ([@B26]; [@B11]; [@B54]). In addition, OATP1A2 and OATP2B1 are also expressed in other CNS cell types. While both transporters have been identified in amacrine neurons of the retina, OATP1A2 was additionally found in hippocampal pyramidal and granule cells ([@B27]). Besides DHEAS, PregS levels in the brain may also be influenced by uptake transporters in the BBB, even though plasma concentrations of PregS were up to two orders of magnitude below the DHEAS levels ([@B80]). Like for DHEAS, OATP-transporters are interesting candidates in this context. While PregS significantly inhibits OATP2B1 function ([@B84]; [@B29]) first reports indicated no direct transport of PregS by this transporter ([@B71]; [@B29]). Interestingly, OATP2B1-mediated transport of E~1~-3-S and DHEAS was stimulated by steroid hormones like progesterone ([@B29]; [@B49]). Under these conditions, PregS was also transported by OATP2B1 ([@B29]). PregS transport by other OATPs has not been studied so far. With regard to the CP only limited information is available about OATP expression and function in humans. In a recent LC-MS/MS-based study examining transporter protein expression in this structure, only OATP3A1 was detected, while OATP1A2 and OATP1C1 were below the detection limit and OATP2B1 was not analyzed ([@B43]). This finding was quite surprising, since in animal models several OATPs have been detected in the CP and shown to be involved in the neurosteroid transport into the liquor ([@B6]; [@B18]; [@B43]). Due to the limited information available, the significance of OATP3A1 in this context cannot be conclusively assessed. However, a transport of E~1~-3-S has also been shown for the OATP3A1 and two splice variants of the transporter are selectively expressed in the apical and basal membrane of the ependymal cells of the CP ([@B86]; [@B37]).

Other Organic Anion Transporters (OSTα-OSTβ, OATs)
--------------------------------------------------

Besides OATPs, an interaction of neurosteroids (mainly DHEAS and PregS) with several further organic anion transporters has been reported. For example, both sulfated neurosteroids have been shown to be transported with high affinity by the organic solute transporter OSTα-OSTβ \[K~m~: 1.5 μM (DHEAS) and 6.9 μM (PregS)\] ([@B25]). The heterodimer OSTα-OSTβ is a relatively new member of the SLC family (SLC51) and encoded by two genes (SLC51A and SLC51B). Like OATPs, the transport mechanism is facilitated diffusion; therefore OSTα-OSTβ-mediated transport is dependent on the electrochemical gradient of its substrates ([@B7]). In the human brain, the transporter is expressed in Purkinje cells and hippocampal neurons ([@B25]). Both regions are well known for their function in the process of learning and memory, and hippocampal neurons have been suggested as a target site for PregS action ([@B2]).

A third group of SLC transporters involved in the CNS distribution of sulfated neurosteroids are the organic anion transporters (OATs), which are part of the SLC22A branch ([@B13]). The pivotal role of these transporters is the excretion of water-soluble organic anions in the kidney. However, selected members are also present in other organs including the brain ([@B13]). In the brain OAT3, is probably the most interesting member of this family. The transporter is expressed in the BBB as well as the CP ([@B3]; [@B47]; [@B88]). In a mouse model, OAT3 was characterized as the DHEAS transporter in part responsible for the DHEAS efflux across the BBB ([@B62]). Besides OAT3, mRNA expression of OAT1 and OAT2 has also been shown for the human brain ([@B59]; [@B3]; [@B21]); however, protein data for these transporters are limited.

Conclusion and Perspectives
===========================

The detailed functions of the described ABC and SLC transporters in brain are still poorly understood. Even data on the expression and localization, e.g., at the BBB are often controversial. Knock-out mice of the ABC and some SLC transporters are available, but have been mainly used to study the role of these transporters for brain penetration of certain drugs ([@B22]; [@B14]). These studies are in part hampered by overlapping substrate specificities of several transporters and with respect to neurosteroids by the fact of negligible levels of sulfated steroids in rodent brain ([@B57]; [@B56]). Furthermore, a number of functional genetic variants in several transporter genes are known ([@B12]); however, their impact on neurosteroid transport is so far largely unknown. Variations in transporter function may affect concentrations and action of several neurosteroids in brain. Therefore, a better understanding of these processes is an important aspect also in the context of a possible therapeutic use of these compounds.
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:   breast cancer resistance protein
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:   estrone-3-sulfate
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